In this part 2, Kirsten Axelsen, MS, discusses racial disparities, AI in prior authorization, and payers’ readiness for the next wave of CLL therapies.
Publication|Articles|December 20, 2023
Supplements and Featured Publications
- Real-World Analysis of Clinical and Economic Outcomes Among Patients Initiating Dual or Triple Therapy for Maintenance of COPD: A Review
Real-World Analysis of Clinical and Economic Outcomes Among Patients Initiating Dual or Triple Therapy for Maintenance of COPD: A Review
Advertisement
This AJMC® clinical brief summarizes pharmacologic treatment recommendations for chronic obstructive pulmonary disease (COPD) and reviews a retrospective claims-based study analyzing differences in clinical and economic outcomes with initiation of dual or triple therapy in patients with COPD.
Advertisement
Related to this article
Kirsten Axelsen, MS, discusses gaps in biomarker testing, nonmedical barriers, and utilization management from a new report on access to CLL care.
A new meta-analysis finds pulmonary rehabilitation and other nonpharmacological interventions ease lung cancer cough, dyspnea, and improve QOL.
Machine learning models for upper extremity soft tissue sarcoma had a C-index of 0.79 for local recurrence, similar to nomograms, in a 188-patient cohort.
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
Merck has begun the phase 3 ENHANCE-3 trial testing whether ensifentrine added to standard of care prevents COPD exacerbations in high-risk adults.
In this Q&A, Christie Ballantyne, MD, explains why consistent LDL-C lowering with oral enlicitide could expand PCSK9 use in primary prevention.
Real-world study tracks JAK inhibitors in alopecia areata and atopic dermatitis, flagging menstrual alterations and weight gain as key safety signals.
Advertisement
Advertisement
Trending on AJMC
1
Real-World Cohort Ties JAK Inhibitors in Alopecia Areata to Menstrual Side Effects
2
Phase 3 Trial Tests Ensifentrine for COPD Exacerbation Prevention
3
Trends in Pharmacy Benefit Manager Market Dynamics, 2016-2025
4
Tarlatamab Plus Durvalumab Cuts Risk of Death by 58% as First-Line Maintenance in ES-SCLC
5